Dopamine versus epinephrine for neonatal septic shock: an open labeled, randomized controlled trial

IF 2.4 3区医学 Q2 OBSTETRICS & GYNECOLOGY

Journal of Perinatology Pub Date : 2025-08-28 DOI:10.1038/s41372-025-02399-7

Gurarsh Singh, Vikram Bhaskar, Prerna Batra, Piyush Gupta

引用次数: 0

Abstract

Septic shock is one of the most common causes of neonatal mortality. Dopamine and epinephrine are the two main drugs used in fluid refractory neonatal septic shock. However, there is lack of consensus on use of first line agent in neonates. This randomized, open labeled, controlled trial was conducted with primary objective to compare the proportion of patients achieving reversal of shock at 60 min of starting either dopamine or epinephrine as first line inotrope in neonates with fluid refractory septic shock. More patients in the epinephrine group achieved reversal of shock than dopamine group (31 vs 25) but the difference was statistically not significant [p = 0.143, RR = 0.806 (95% CI 0.602,1.080)]. All-cause mortality was 87.5% (35/40) in the dopamine group and 85% (34/40) in the epinephrine group (34/40). Dopamine and epinephrine show equivalent efficacy in reversal of shock at 60 min in neonates with septic shock.

Abstract Image

查看原文本刊更多论文

多巴胺与肾上腺素治疗新生儿感染性休克：一项开放标记、随机对照试验。

感染性休克是新生儿死亡的最常见原因之一。多巴胺和肾上腺素是治疗难治性新生儿感染性休克的两种主要药物。然而，对于在新生儿中使用一线药物缺乏共识。研究设计：这项随机、开放标记、对照试验的主要目的是比较在新生儿液体难治性感染性休克开始使用多巴胺或肾上腺素作为一线肌力药物60分钟后休克逆转的患者比例。结果：肾上腺素组患者休克逆转率高于多巴胺组（31 vs 25），但差异无统计学意义[p = 0.143, RR = 0.806 (95% CI 0.602,1.080)]。多巴胺组全因死亡率为87.5%(35/40)，肾上腺素组全因死亡率为85%（34/40）。结论：多巴胺与肾上腺素在新生儿感染性休克60 min休克逆转中疗效相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Perinatology 医学-妇产科学

CiteScore

5.40

自引率

6.90%

发文量

284

审稿时长

3-8 weeks

期刊介绍： The Journal of Perinatology provides members of the perinatal/neonatal healthcare team with original information pertinent to improving maternal/fetal and neonatal care. We publish peer-reviewed clinical research articles, state-of-the art reviews, comments, quality improvement reports, and letters to the editor. Articles published in the Journal of Perinatology embrace the full scope of the specialty, including clinical, professional, political, administrative and educational aspects. The Journal also explores legal and ethical issues, neonatal technology and product development. The Journal’s audience includes all those that participate in perinatal/neonatal care, including, but not limited to neonatologists, perinatologists, perinatal epidemiologists, pediatricians and pediatric subspecialists, surgeons, neonatal and perinatal nurses, respiratory therapists, pharmacists, social workers, dieticians, speech and hearing experts, other allied health professionals, as well as subspecialists who participate in patient care including radiologists, laboratory medicine and pathologists.